These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37671127)

  • 1. Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort.
    Joy M; Agrawal U; Fan X; Robertson C; Anand SN; Ordonez-Mena J; Byford R; Goudie R; Jamie G; Kar D; Williams J; Marsden GL; Tzortziou-Brown V; Sheikh SA; Hobbs FDR; de Lusignan S
    Lancet Reg Health Eur; 2023 Sep; 32():100681. PubMed ID: 37671127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
    Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
    BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Simpson CR; Kerr S; Katikireddi SV; McCowan C; Ritchie LD; Pan J; Stock SJ; Rudan I; Tsang RSM; de Lusignan S; Hobbs FDR; Akbari A; Lyons RA; Robertson C; Sheikh A
    Nat Commun; 2022 Aug; 13(1):4800. PubMed ID: 35970827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales.
    Torabi F; Bedston S; Lowthian E; Akbari A; Owen RK; Bradley DT; Agrawal U; Collins P; Fry R; Griffiths LJ; Beggs J; Davies G; Hollinghurst J; Lyons J; Abbasizanjani H; Cottrell S; Perry M; Roberts R; Azcoaga-Lorenzo A; Fagbamigbe AF; Shi T; Tsang RSM; Robertson C; Hobbs FDR; de Lusignan S; McCowan C; Gravenor M; Simpson CR; Sheikh A; Lyons RA
    Sci Rep; 2022 Sep; 12(1):16406. PubMed ID: 36180455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    Whiteley WN; Ip S; Cooper JA; Bolton T; Keene S; Walker V; Denholm R; Akbari A; Omigie E; Hollings S; Di Angelantonio E; Denaxas S; Wood A; Sterne JAC; Sudlow C;
    PLoS Med; 2022 Feb; 19(2):e1003926. PubMed ID: 35192597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Simpson CR; Shi T; Vasileiou E; Katikireddi SV; Kerr S; Moore E; McCowan C; Agrawal U; Shah SA; Ritchie LD; Murray J; Pan J; Bradley DT; Stock SJ; Wood R; Chuter A; Beggs J; Stagg HR; Joy M; Tsang RSM; de Lusignan S; Hobbs R; Lyons RA; Torabi F; Bedston S; O'Leary M; Akbari A; McMenamin J; Robertson C; Sheikh A
    Nat Med; 2021 Jul; 27(7):1290-1297. PubMed ID: 34108714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
    Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
    Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
    BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
    Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.
    Bouillon K; Baricault B; Botton J; Jabagi MJ; Bertrand M; Semenzato L; Le Vu S; Drouin J; Dray-Spira R; Weill A; Zureik M
    BMJ Med; 2022; 1(1):e000104. PubMed ID: 36936561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.
    Dag Berild J; Bergstad Larsen V; Myrup Thiesson E; Lehtonen T; Grøsland M; Helgeland J; Wolhlfahrt J; Vinsløv Hansen J; Palmu AA; Hviid A
    JAMA Netw Open; 2022 Jun; 5(6):e2217375. PubMed ID: 35699955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
    Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study.
    Ab Rahman N; Lim MT; Lee FY; Wo WK; Yeoh HS; Peariasamy KM; Sivasampu S;
    Sci Rep; 2023 Nov; 13(1):20471. PubMed ID: 37993548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study.
    Tsang RS; Agrawal U; Joy M; Byford R; Robertson C; Anand SN; Hinton W; Mayor N; Kar D; Williams J; Victor W; Akbari A; Bradley DT; Murphy S; O'Reilly D; Owen RK; Chuter A; Beggs J; Howsam G; Sheikh A; Richard Hobbs FD; Lusignan S
    J R Soc Med; 2024 Apr; 117(4):134-148. PubMed ID: 37921538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination.
    Krzywicka K; van de Munckhof A; Sánchez van Kammen M; Heldner MR; Jood K; Lindgren E; Tatlisumak T; Putaala J; Kremer Hovinga JA; Middeldorp S; Levi MM; Cordonnier C; Arnold M; Zwinderman AH; Ferro JM; Coutinho JM; Aguiar de Sousa D
    Neurology; 2022 Feb; 98(7):e759-e768. PubMed ID: 34921101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.